TeenCove reached end point…..

By May 26, 2021November 3rd, 2022Covid-19 News

Moderna announced this week that their SARS-CoV-2 vaccine trial in adolescents, TeenCOVE, has reached its primary endpoint. More than 3,700 adolescents aged 12 to less than 18 years old were enrolled in the trial. No cases of COVID-19 were recorded in vaccine recipients following two doses of the Moderna vaccine. With these results indicating an efficacy of 100% 14 days after both doses, Moderna also found approximately 93% efficacy following one dose of the vaccine. The company plans to send the trial data to regulators in early June. Moderna would be the second SARS-CoV-2 vaccine to be authorized for use in adolescents in the US, following Pfizer-BioNTech’s authorization earlier in May. Both Moderna and Pfizer-BioNTech are investigating vaccine safety and efficacy in children aged 6 months to 11 years, but those results are not expected for some time due to the need to adjust dosing amounts.

CSSE is reporting 33,161,461 positive cases in the U.S. and 590,877 deaths. DOH reported 2,313,815 confirmed cases in Florida today, with 36,581 deaths.